Observational analysis showed improved cardiometabolic control in patients with type 2 diabetes on dapagliflozin, suggesting better outcomes than standard antidiabetic therapy.
Key Points
Cardiometabolic control improved significantly with dapagliflozin, with 21.8% achievement rate versus only 1.9% for standard care.
Dapagliflozin users experienced a notable HbA1c drop and weight loss compared to the control group within 26 weeks of treatment.
This ambispective observational study included 535 patients with type 2 diabetes across multiple follow-up visits.
Findings support dapagliflozin's safety profile and its role in complex diabetes management.